Sunbin Ling
Overview
Explore the profile of Sunbin Ling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
895
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao J, Sun R, Zhi L, Guo D, Ling S, Liang X, et al.
Future Oncol
. 2024 Dec;
21(3):331-340.
PMID: 39706798
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths, with high rates of postoperative recurrence. Identifying reliable biomarkers for predicting recurrence is critical for improving patient outcomes. This...
2.
Xu S, Shu W, He X, Ling S, Wei X, Xu X
Chin Med J (Engl)
. 2024 Oct;
137(22):2651-2653.
PMID: 39450898
No abstract available.
3.
Hong J, Yu J, Buratto D, Chen W, Zhou R, Ling S, et al.
Int J Biol Sci
. 2024 Oct;
20(13):5239-5253.
PMID: 39430235
Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world and the third leading cause of cancer deaths globally. More than 80% of HCC patients have a background...
4.
Shan Q, Yin L, Zhan Q, Yu J, Pan S, Zhuo J, et al.
Signal Transduct Target Ther
. 2024 Sep;
9(1):249.
PMID: 39300073
Lenvatinib is a targeted drug used for first-line treatment of hepatocellular carcinoma (HCC). A deeper insight into the resistance mechanism of HCC against lenvatinib is urgently needed. In this study,...
5.
Zhang L, Zhou W, Zheng S, Ling S, Xu X
Chin Med J (Engl)
. 2024 May;
137(16):1973-1975.
PMID: 38763768
No abstract available.
6.
mTOR inhibitor reduces nontumour-related death in liver transplantation for hepatocellular carcinoma
Zhang L, Liu P, Zhuang L, Ling S, Zhan Q, Zhou W, et al.
Mol Biomed
. 2024 Mar;
5(1):9.
PMID: 38461206
Sirolimus is a regularly applied immunosuppressant for patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC). Sirolimus not only significantly inhibits HCC recurrence but also protects renal function. However, the...
7.
Bao J, Zhao Y, Xu X, Ling S
Curr Med Chem
. 2024 Feb;
PMID: 38299294
Metformin is a first-line drug for the treatment of type 2 diabetes with a good safety profile and relatively low cost. In recent years, many other effects of metformin have...
8.
Ye Q, Zhou W, Xu S, Que Q, Zhan Q, Zhang L, et al.
MedComm (2020)
. 2023 Dec;
4(6):e439.
PMID: 38045832
Ubiquitin-specific protease 22 (USP22) has been identified as a potential marker for cancer stem cells in hepatocellular carcinoma (HCC). It can promote HCC stemness, which is considered a driver of...
9.
Yu J, Ling S, Hong J, Zhang L, Zhou W, Yin L, et al.
J Immunother Cancer
. 2023 Nov;
11(11).
PMID: 38030304
Background: Immunotherapy has facilitated great breakthroughs in the treatment of hepatocellular carcinoma (HCC). However, the efficacy and response rate of immunotherapy are limited and vary among different patients with HCC....
10.
He X, Xu S, Tang L, Ling S, Wei X, Xu X
Int J Surg
. 2023 Oct;
110(1):406-418.
PMID: 37800536
Research on liver transplantation (LT) for liver cancer has gained increasing attention. This paper has comprehensively described the current status, hotspots and trends in this field. A total of 2991...